<DOC>
	<DOCNO>NCT01244815</DOCNO>
	<brief_summary>Efficacy safety asenapine treatment bipolar I disorder ( manic mixed episode ) evaluate participant 10 17 year old , either hospitalize non-hospitalized . In 3-weeks , double-blind , parallel design trial , eligible participant randomize receive one three fix dose level asenapine , placebo . The study primary hypothesis least one asenapine dose superior placebo measure change baseline Day 21 Young Mania Rating Scale ( Y-MRS ) total score . Trial medication placebo provide identical-looking sublingual tablet ; concurrent use psychotropics prohibit , except use short-acting benzodiazepine psychostimulants approve treatment attention deficit hyperactivity disorder ( ADHD ) . Main treatment effect measure use Y-MRS safety evaluate use recording adverse event , routine blood panel , physical examination ( include vital sign ) , electrocardiograms . Participants complete double blind trial may offer continue ( open-label ) treatment asenapine extend period time . Follow-up information safety parameter collect participant within 30 day follow treatment discontinuation .</brief_summary>
	<brief_title>Efficacy Safety Asenapine Treatment Pediatric Bipolar Disorder ( P06107 Has Extension P05898 ; NCT01349907 ) ( P06107 )</brief_title>
	<detailed_description>Participants ' Y-MRS total score baseline subtract Day 21 visit determine amount change time treatment . The response 3 different asenapine dos compare placebo evaluate . The Y-MRS 11 item scale : seven item rank scale 0 4 four item rank 0 8 range possible total score 0 60 . Participants ' overall score CGI-BP Day 21 evaluate determine amount change time treatment . The response 3 different asenapine dos compare placebo evaluate . CGI-BP overall score obtain single-item clinician-rated scale use ass participant 's overall bipolar illness . Scores range ill ( 1 ) severely ill ( 7 ) . The proportion participant whose total Y-MRS score decrease ≥50 % baseline Day 4 , 7 , 14 21 . Results 3 different asenapine dos compare placebo evaluate . Participants ' mania sub-score CGI-BP evaluate study visit ( Days 4 , 7 , 14 21 ) determine amount change time treatment . The response 3 different asenapine dos compare placebo evaluate . Participants ' depression sub-score CGI-BP evaluate study visit ( Days 4 , 7 , 14 21 ) determine amount change time treatment . The response 3 different asenapine dos compare placebo evaluate . Participants ' CDRS-R baseline subtract study visit rating measure ( Days 7 , 14 21 ) determine amount change time treatment . The response 3 different asenapine dos compare placebo evaluate . The CDRS-R 17-item scale ass presence severity depressive symptom : fourteen item rat 1 7 three item rat 1 5 ; total score range 17 113 . Participants ' CGAS baseline subtract Day 21 visit determine amount change time treatment . The response 3 different asenapine dos compare placebo evaluate . The CGAS 100-point scale , possible range 1 100 . Normal social functioning define CGAS total score ≥70 . Participants ' PQ-LES-Q total score baseline subtract Day 21 visit determine amount change time treatment . The response 3 different asenapine dos compare placebo evaluate . The PQ-LES-Q 15-item scale , total score calculate sum first 14 item , range 14 70 . Each item score child 1 5 , high score indicative great enjoyment satisfaction . Participants ' PQ-LES-Q overall score ( i.e . item 15 ) baseline subtract Day 21 visit determine amount change time treatment . The response 3 different asenapine dos compare placebo evaluate . The PQ-LES-Q overall score determine answer item 15 questionnaire ( range : 1 5 ) .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Asenapine</mesh_term>
	<criteria>Inclusion criterion : Participants ( whose parent/legal representative ) able give write informed consent . Participants must 10 year age old 17 year age young time treatment assignment ( randomization ) . Participants must diagnosis bipolar I disorder , confirm structure interview screen . Participants must pregnant lactating , sexually active become sexually active trial , childbearing potential , must use medically accept form birth control . Participants require stop take certain psychoactive medication prior baseline . Participants must caregiver , responsible person live agrees provide support participant ensure study procedure compliance . Exclusion criterion : Diagnosis bipolar II disorder , form bipolar psychotic disorder . Known suspected mental retardation . Substance abuse , dependence , within past 6 month . There risk selfharm harm others . There history tardive dyskinesia dystonia . Pregnancy lactation study . History seizure disorder . Participation clinical trial time . A family member part study staff directly involve study . Other medical condition determine study staff possibly interfere study safety efficacy evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Bi-polar I disorder</keyword>
	<keyword>antipsychotic</keyword>
	<keyword>serotonin</keyword>
	<keyword>dopamine</keyword>
	<keyword>noradrenalin</keyword>
	<keyword>histamine</keyword>
	<keyword>pediatric</keyword>
</DOC>